A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Inclusion Criteria:

• Age ≥18 years.

• ECOG performance status of 0 or 1.

• Histologically confirmed:

• Clear cell renal cell carcinoma (ccRCC).

• Diffuse large B-cell lymphoma (DLBCL, NOS).

• High-grade B-cell lymphoma (HGBCL).

• Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).

• Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 bloodinvolvement).

• Disease progression, relapse, or refractory to prior therapy:

• ccRCC: ≥1 prior line incl. ICI + TKI.

• DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.

• PTCL/CTCL: ≥1 prior systemic therapy.

• Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), orISCL/USCLC/EORTC (CTCL).

• Tumor tissue available for central testing.

Exclusion Criteria:

• Untreated or progressive CNS disease unless previously treated and stable.

• Other active invasive malignancy within 2 years (except certain low-risk cancers).

• Prior CD70-targeting therapy, including CAR T.

• ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.

• Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).

• Primary immunodeficiency or active autoimmune disease requiring immunosuppression.

• Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.

• Pregnancy, breastfeeding, or unwillingness to use effective contraception.

Other protocol-defined Inclusion/Exclusion Criteria may apply.